Join our expert panel as they discuss the future of type 2 diabetes, what is the evolving role of continuous glucose monitoring (CGM) in type 2 and what treatment options will support patients and their health care professionals to improve patient outcomes.

With / speaker(s);

Dr. Jackie Elliot is a Clinical Lead for Diabetes, Senior Clinical Lecturer, and Honorary Consultant at Sheffield Teaching Hospitals NHS Foundation Trust.

Dr Sarah Davies GP Partner at Woodlands Medical Centre in Cardiff, Clinical Director for Diabetes for the Primary, Community and Intermediate Care board at Cardiff and Vale UHB, All Wales Primary Care lead for Diabetes.

Prof Sam Seidu Professor in Primary Care Diabetes and Cardio-metabolic Medicine, University of Leicester/ GP
Waqas Tahir, GP Partner/Diabetes Clinical Lead at Affinity Care/West Yorkshire ICB.

*If your glucose alerts and readings from Dexcom CGM System do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

Jackie Elliot Study
Elliott J. et al Clinical outcomes of a real-world prospective study using Dexcom ONE continuous glucose monitoring in people with diabetes treated with two or more insulin injections per day. Diabet Med. 2025.e15519.

NICE. Type 2 diabetes in adults: management. Accessed March, 2025.
https://www.nice.org.uk/guidance/ng28

† © NICE [2023]. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

MAT-7897

Hear what we have coming up in Season 3 of the Diabetes Dialogues podcast.

This podcast has been created and fully funded by Dexcom UK & Ireland and intended for healthcare professionals practising in the United Kingdom & Ireland.

Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice.

All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom User Guide . For product-related questions, please refer to the instructions for use. For complete safety information, go to https://www.dexcom.com/en-gb/safety-information . Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. © 2025 Dexcom, Inc. All rights reserved. Dexcom Distribution Ltd, www.dexcom.com.

Further CPD accredited education can be found on the Dexcom Education Hub

Adam Dawes speaks to Professor Sam Seidu about the financial impact of managing Type 2 diabetes within the NHS system. Looking at direct and indirect costs, the importance of early intervention, and the challenges of sustaining high-cost treatments like GLP-1 receptor agonists and continuous glucose monitoring (CGM). A great introduction to heath economics around diabetes within the UK health system.

With speaker; Prof.Sam Seidu Professor in Primary Care Diabetes and Cardio-metabolic Medicine, University of Leicester/ GP

*If your glucose alerts and readings from Dexcom CGM System do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.


NICE. Type 2 diabetes in adults: management. Accessed March, 2025.
https://www.nice.org.uk/guidance/ng28

† © NICE [2023]. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

MAT-7903

Hear what we have coming up in Season 3 of the Diabetes Dialogues podcast.

This podcast has been created and fully funded by Dexcom UK & Ireland and intended for healthcare professionals practising in the United Kingdom & Ireland.

Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice.

All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom User Guide . For product-related questions, please refer to the instructions for use. For complete safety information, go to https://www.dexcom.com/en-gb/safety-information . Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. © 2025 Dexcom, Inc. All rights reserved. Dexcom Distribution Ltd, www.dexcom.com.

Further CPD accredited education can be found on the Dexcom Education Hub

This podcast discusses how diabetes specialists and general practitioners can collaborate to manage patients with type 2 diabetes effectively. Dr. Jackie Elliot and Dr. Sarah Davies share their insights on the importance of specialist care for complex cases and the role of general practice in managing the majority of patients. A really great insight from two very experienced healthcare professionals that to help you navigate the changing role of general practice in diabetes management.

With / speaker;

Dr. Jackie Elliot is a Clinical Lead for Diabetes, Senior Clinical Lecturer, and Honorary Consultant at Sheffield Teaching Hospitals NHS Foundation Trust.
Dr Sarah Davies GP Partner at Woodlands Medical Centre in Cardiff, Clinical Director for Diabetes for the Primary, Community and Intermediate Care board at Cardiff and Vale UHB, All Wales Primary Care lead for Diabetes.

*If your glucose alerts and readings from Dexcom CGM System do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

Jackie Elliot Study
Elliott J. et al Clinical outcomes of a real-world prospective study using Dexcom ONE continuous glucose monitoring in people with diabetes treated with two or more insulin injections per day. Diabet Med. 2025.e15519.

NICE. Type 2 diabetes in adults: management. Accessed March, 2025.
https://www.nice.org.uk/guidance/ng28

† © NICE [2023]. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

MAT-7898

This podcast has been created and fully funded by Dexcom UK & Ireland and intended for healthcare professionals practising in the United Kingdom & Ireland.

Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice.

All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom User Guide . For product-related questions, please refer to the instructions for use. For complete safety information, go to https://www.dexcom.com/en-gb/safety-information . Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. © 2025 Dexcom, Inc. All rights reserved. Dexcom Distribution Ltd, www.dexcom.com.

Further CPD accredited education can be found on the Dexcom Education Hub